{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:10:43Z","timestamp":1782627043762,"version":"3.54.5"},"reference-count":81,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,29]]},"DOI":"10.18632\/oncotarget.17634","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T14:20:25Z","timestamp":1493994025000},"page":"58709-58727","source":"Crossref","is-referenced-by-count":57,"title":["Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions"],"prefix":"10.18632","volume":"8","author":[{"given":"Chen","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York University Langone Medical Center, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Division of Ophthalmology, The University of Texas MD Anderson Cancer Center, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goldy C.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Phase I Clinical Trials, The University of Texas MD Anderson Cancer Center, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whyte","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Division of Ophthalmology, The University of Texas MD Anderson Cancer Center, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Phase I Clinical Trials, The University of Texas MD Anderson Cancer Center, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"key":"1","unstructured":"Centerwatch Database of FDA Approved Drugs. http:\/\/www.centerwatch.com."},{"key":"2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ctrv.2013.05.005","article-title":"Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders","volume":"40","author":"Garassino","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G","article-title":"Ocular toxicity and cancer chemotherapy. A review","volume":"78","author":"Mackey","year":"1996","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Bedard","year":"2012","journal-title":"J Clin Oncol"},{"key":"5","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am Fam Physician"},{"key":"6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Le Tourneau","year":"2014","journal-title":"Eur J Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard","volume":"7","author":"Loke","year":"2012","journal-title":"PLoS One"},{"key":"8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Tortora","year":"2008","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.NCC.0000281759.23823.82","article-title":"Ocular toxicities of epidermal growth factor receptor inhibitors and their management","volume":"30","author":"Basti","year":"2007","journal-title":"Cancer Nurs"},{"key":"10","first-page":"146","article-title":"Epidermal growth factor and its receptors family on the ocular surface","volume":"15","author":"Xie","year":"1999","journal-title":"Yan Ke Xue Bao"},{"key":"11","first-page":"953","article-title":"[Role of epidermal growth factor and its receptor family in ocular surface wound healing]. [Article in Chinese]","volume":"43","author":"Liu","year":"2007","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF-MEK-ERK pathway in cancer therapy","volume":"283","author":"Settleman","year":"2009","journal-title":"Cancer Lett"},{"key":"13","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Der","year":"2007","journal-title":"Oncogene"},{"key":"14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","article-title":"Association between bortezomib therapy and eyelid chalazia","volume":"134","author":"Yang","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"15","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.4081\/hr.2015.5729","article-title":"Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy","volume":"7","author":"Olcay","year":"2015","journal-title":"Hematol Rep"},{"key":"16","first-page":"e3","article-title":"Chalazia associated with bortezomib therapy for multiple myeloma","volume":"121","author":"Yoon","year":"2014","journal-title":"Ophthalmology"},{"key":"17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-015-0049-9","article-title":"Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib","volume":"5","author":"Willermain","year":"2015","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Franke","year":"2014","journal-title":"Lancet Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Mieler","year":"2011","journal-title":"Ophthalmology"},{"key":"20","first-page":"56","article-title":"Ocular toxicity of ethambutol","volume":"12","author":"Kwok","year":"2006","journal-title":"Hong Kong Med J"},{"key":"21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"Schellens","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"22","volume-title":"Common terminology criteria for adverse events (CTCAE)","author":"National Cancer Institute (U.S.)","year":"2009"},{"key":"23","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1200\/JCO.2013.49.1985","article-title":"Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation","volume":"33","author":"Timmerman","year":"2015","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/2.1.45","article-title":"The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery","volume":"2","author":"Groothuis","year":"2000","journal-title":"Neuro Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"MAbs"},{"key":"27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4161\/onci.20687","article-title":"Ipilimumab in a Phase II trial of melanoma patients with brain metastases","volume":"1","author":"Margolin","year":"2012","journal-title":"Oncoimmunology"},{"key":"28","doi-asserted-by":"crossref","first-page":"8448","DOI":"10.4049\/jimmunol.177.12.8448","article-title":"NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain","volume":"177","author":"Ribas","year":"2006","journal-title":"J Immunol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1172\/JCI41911","article-title":"Trafficking of immune cells in the central nervous system","volume":"120","author":"Hunter","year":"2010","journal-title":"J Clin Invest"},{"key":"30","unstructured":"Gilotrif (Afatinib) FDA Package Insert. Germany, Boehringer Ingelheim Pharmaceuticals, Inc. 2013."},{"key":"31","unstructured":"Bortezomib (Velcade) FDA Package Insert. Cambridge, MA, Millennium Pharmaceutical. 2014."},{"key":"32","unstructured":"Zykadia (Ceritinib) FDA Package Insert. Basel, Switzerland, Novartis. 2015."},{"key":"33","unstructured":"Xalkori Crizotinib FDA Package Insert. New York City, NY, Pfizer. 2014."},{"key":"34","unstructured":"Dabrafenib (Tafinlar) FDA Package Insert. Brentford, UK, GlaxoSmithKline. 2014."},{"key":"35","unstructured":"Sprycel Dasatinib FDA Package Insert. New York City, NY, Bristol-Myers Squibb. 2015."},{"key":"36","volume-title":"FDA Package Insert","author":"Erlotinib","year":"2013"},{"key":"37","volume-title":"FDA Package Insert","author":"Gefitinib","year":"2015"},{"key":"38","volume-title":"FDA Package Insert","author":"Imatinib","year":"2015"},{"key":"39","volume-title":"FDA Package Insert","author":"Nilotinib","year":"2010"},{"key":"40","volume-title":"FDA Label Insert","author":"Trametinib","year":"2014"},{"key":"41","volume-title":"FDA Package Insert","author":"Vandetanib","year":"2014"},{"key":"42","unstructured":"Zelboraf Vemurafenib FDA Package Insert. San Francisco, CA, Genentech. 2014."},{"key":"43","unstructured":"Erbitux Cetuximab FDA Package Insert. New York City, NY, Bristol-Myers Squibb. 2013."},{"key":"44","unstructured":"Yervoy Ipilimumab FDA Package Insert. New York City, NY, Bristol-Myers Squibb. 2015."},{"key":"45","unstructured":"Vectibix Panitumumab FDA Package Insert. Thousand Oaks, CA, Amgen. 2014."},{"key":"46","unstructured":"Perjeta Pertuzumab FDA Package Insert. San Francisco, CA, Genentech. 2013."},{"key":"47","unstructured":"Rituxan Rituximab FDA Package Insert. San Francisco, CA, Genentech. 2014."},{"key":"48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.2014.902445","article-title":"Afatinib for the treatment of advanced non-small-cell lung cancer","volume":"15","author":"Grossi","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"49","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Ebisawa","year":"2013","journal-title":"J Clin Oncol"},{"key":"50","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdu216","article-title":"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"25","author":"Cohen","year":"2014","journal-title":"Ann Oncol"},{"key":"51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Wolf","year":"2014","journal-title":"N Engl J Med"},{"key":"52","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma","volume":"126","author":"Solomon","year":"2015","journal-title":"Blood"},{"key":"53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1060028014553619","article-title":"Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer","volume":"49","author":"Durand","year":"2015","journal-title":"Ann Pharmacother"},{"key":"54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Engelman","year":"2012","journal-title":"Lancet Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"O\u2019Byrne","year":"2013","journal-title":"N Engl J Med"},{"key":"56","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Boque","year":"2010","journal-title":"N Engl J Med"},{"key":"57","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Chen","year":"2006","journal-title":"N Engl J Med"},{"key":"58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Giaccone","year":"2010","journal-title":"Lancet Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Chao","year":"2012","journal-title":"Lancet Oncol"},{"key":"60","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Bonomi","year":"2004","journal-title":"J Clin Oncol"},{"key":"61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Garrido","year":"2012","journal-title":"Lancet Oncol"},{"key":"62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Findlay","year":"2005","journal-title":"N Engl J Med"},{"key":"63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Osterlind","year":"2008","journal-title":"Lancet"},{"key":"64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Yang","year":"2009","journal-title":"N Engl J Med"},{"key":"65","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Carroll","year":"2005","journal-title":"Lancet"},{"key":"66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Phase I and II clinical trials","volume":"19","author":"Faulkner","year":"2005","journal-title":"Eye (Lond)"},{"key":"67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"68","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Corless, Ballman, Antonescu, Blanke, Blackstein, Demetri, von Mehren, Maki, Pisters, DeMatteo. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. 2010 ASCO Annual Meeting. 2010.","DOI":"10.1200\/jco.2010.28.15_suppl.10006"},{"key":"70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Kuyl","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"71","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Dong","year":"2010","journal-title":"N Engl J Med"},{"key":"72","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Le","year":"2012","journal-title":"Lancet Oncol"},{"key":"73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Larkin","year":"2012","journal-title":"N Engl J Med"},{"key":"74","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Hart","year":"2012","journal-title":"Lancet Oncol"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Michalarea, de Miguel Luken, Diamantis, Garg, Maubon, Yap, Molife, De Bono, Ursell, Banerji. Ocular toxicity with MEK inhibitors in phase I trials: a single centre experience across six clinical trials. 2015 ASCO Annual Meeting. 2015.","DOI":"10.1200\/jco.2015.33.15_suppl.11090"},{"key":"76","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary","volume":"18","author":"Booth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Hospers","year":"2014","journal-title":"Lancet Oncol"},{"key":"78","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"Maio","year":"2014","journal-title":"Lancet Oncol"},{"key":"79","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Meropol","year":"2007","journal-title":"Cancer"},{"key":"80","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Shuman","year":"2007","journal-title":"J Clin Oncol"},{"key":"81","volume-title":"FDA Package Insert","author":"Ibrutinib","year":"2015"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T07:43:18Z","timestamp":1658994198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":81,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8,29]]}},"alternative-id":["17634","28938590"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17634","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,5]]}}}